- Home
- BCLI vs EYEN Comparison
BCLI vs EYEN Comparison
Compare BCLI & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- EYEN
- Stock Information
- Founded
- BCLI 2000
- EYEN 2014
- Country
- BCLI United States
- EYEN United States
- Employees
- BCLI N/A
- EYEN N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- EYEN Health Care
- Exchange
- BCLI Nasdaq
- EYEN Nasdaq
- Market Cap
- BCLI 9.1M
- EYEN 9.2M
- IPO Year
- BCLI N/A
- EYEN 2018
- Fundamental
- Price
- BCLI $2.25
- EYEN $0.08
- Analyst Decision
- BCLI Strong Buy
- EYEN Hold
- Analyst Count
- BCLI 1
- EYEN 4
- Target Price
- BCLI $30.00
- EYEN $2.00
- AVG Volume (30 Days)
- BCLI 112.8K
- EYEN 19.0M
- Earning Date
- BCLI 11-14-2024
- EYEN 11-12-2024
- Dividend Yield
- BCLI N/A
- EYEN N/A
- EPS Growth
- BCLI N/A
- EYEN N/A
- EPS
- BCLI N/A
- EYEN N/A
- Revenue
- BCLI N/A
- EYEN $31,832.00
- Revenue This Year
- BCLI N/A
- EYEN $23,413.60
- Revenue Next Year
- BCLI N/A
- EYEN $400.98
- P/E Ratio
- BCLI N/A
- EYEN N/A
- Revenue Growth
- BCLI N/A
- EYEN 2557.10
- 52 Week Low
- BCLI $1.05
- EYEN $0.08
- 52 Week High
- BCLI $11.85
- EYEN $2.57
- Technical
- Relative Strength Index (RSI)
- BCLI 70.03
- EYEN 27.49
- Support Level
- BCLI $1.45
- EYEN $0.08
- Resistance Level
- BCLI $1.72
- EYEN $0.09
- Average True Range (ATR)
- BCLI 0.18
- EYEN 0.01
- MACD
- BCLI 0.08
- EYEN 0.01
- Stochastic Oscillator
- BCLI 84.69
- EYEN 13.08
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.